LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Elenco Azioni・Roivant Sciences Ltd

Roivant Sciences Ltd

Chiusa

SettoreSettore sanitario

28.59 -3.15

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

28.59

Massimo

29.6

Metriche Chiave
By Trading Economics
Entrata	669M 356M
Vendite	521K 2.5M
Margine di Profitto	14,116.825
Dipendenti	721
EBITDA	-65M -354M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+23.7% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	32M 20B
Apertura precedente	31.74
Chiusura precedente	28.59

Notizie sul Sentiment di mercato

By Acuity

24%

76%

56 / 344 Classifica in Healthcare

Roivant Sciences Ltd Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 giu 2026, 19:20 UTC

I principali Market Mover

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5 giu 2026, 21:27 UTC

Utili

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 giu 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

5 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

5 giu 2026, 20:20 UTC

Acquisizioni, Fusioni, Takeovers

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 giu 2026, 20:19 UTC

Acquisizioni, Fusioni, Takeovers

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 giu 2026, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

5 giu 2026, 19:26 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

5 giu 2026, 19:26 UTC

Discorsi di Mercato

Hog Futures Tumble to Close Week -- Market Talk

5 giu 2026, 19:10 UTC

Discorsi di Mercato

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 giu 2026, 19:03 UTC

Discorsi di Mercato

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 giu 2026, 18:59 UTC

Discorsi di Mercato

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 giu 2026, 18:47 UTC

Discorsi di Mercato

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 giu 2026, 18:34 UTC

Discorsi di Mercato

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 giu 2026, 18:33 UTC

Acquisizioni, Fusioni, Takeovers

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 giu 2026, 17:50 UTC

Utili

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 giu 2026, 17:27 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 giu 2026, 16:48 UTC

Acquisizioni, Fusioni, Takeovers

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 giu 2026, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

5 giu 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

5 giu 2026, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

5 giu 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

5 giu 2026, 15:44 UTC

Acquisizioni, Fusioni, Takeovers

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 giu 2026, 15:26 UTC

Discorsi di Mercato

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 giu 2026, 15:25 UTC

Utili

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 giu 2026, 15:16 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

5 giu 2026, 15:16 UTC

Discorsi di Mercato

Zcash Tumbles After Exploit Found -- Market Talk

5 giu 2026, 15:09 UTC

Discorsi di Mercato

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5 giu 2026, 15:07 UTC

Discorsi di Mercato

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5 giu 2026, 15:05 UTC

Discorsi di Mercato

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Confronto tra pari

Modifica del prezzo

Roivant Sciences Ltd Previsione

Obiettivo di Prezzo

By TipRanks

23.7% in crescita

Previsioni per 12 mesi

Media 36.53 USD 23.7%

Alto 42 USD

Basso 29.29 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

56 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.